Patents by Inventor Xuling ZHU

Xuling ZHU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
    Publication number: 20230323371
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Application
    Filed: April 6, 2023
    Publication date: October 12, 2023
    Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
  • Polynucleotides encoding ?-galactosidase A for the treatment of Fabry disease
    Patent number: 11649461
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: May 16, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain Mcfadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
  • POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
    Publication number: 20200149052
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Application
    Filed: September 13, 2019
    Publication date: May 14, 2020
    Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
  • Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
    Patent number: 10519455
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: December 31, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
  • Polynucleotides encoding ?-galactosidase A for the treatment of Fabry disease
    Patent number: 10494636
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: December 3, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
  • POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
    Publication number: 20190000933
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Application
    Filed: August 23, 2018
    Publication date: January 3, 2019
    Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
  • POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
    Publication number: 20190000932
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Application
    Filed: August 23, 2018
    Publication date: January 3, 2019
    Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
  • POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
    Publication number: 20190002890
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Application
    Filed: August 23, 2018
    Publication date: January 3, 2019
    Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS